Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page’s release/version indicator was incremented from “v3.5.2” to “v3.5.3,” reflecting a minor site revision rather than a change to the study record.SummaryDifference0.1%

- Check27 days agoChange DetectedSite revision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check55 days agoChange DetectedThe revision history is updated to include v3.5.0 as the latest revision and removes v3.4.3.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page revision label was updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check91 days agoChange DetectedThe study status was updated to Completed with actual completion dates, replacing the previous 'Active, not recruiting' status. The page revision was updated to v3.4.2 and the funding-status notice was removed.SummaryDifference0.8%

- Check98 days agoChange DetectedA government funding status notice banner was added and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.